68 Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy

• Published in: Biomedicines 2020-11, Vol.8 (12)
• Main Authors: Caroli, Paola, Colangione, Sarah Pia, De Giorgi, Ugo, Ghigi, Giulia, Celli, Monica, Scarpi, Emanuela, Monti, Manuela, Di Iorio, Valentina, Sarnelli, Anna, Paganelli, Giovanni, Matteucci, Federica, Romeo, Antonino
• Format: Article
• Language: English
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines8120536

(1) Purpose: To investigate the role of Ga-PSMA-11 PET/CT in guiding retreatment stereotactic body radiation therapy (SBRT) in prostate cancer (PCa) patients in biochemical recurrence (BCR) after salvage radiotherapy (S-RT). (2) Methods: We retrospectively evaluated PCa patients previously treated with S-RT on the prostate bed and with proven serum prostate antigen (PSA) failure after S-RT. In all patients (pts), Ga-PSMA-11 PET/CT was positive in the prostate bed only and guided retreatment SBRT. All retreatments were performed by applying the same radiotherapy protocol (median dose of 18 Gy/3 fractions; IQR 18-21 Gy). The median follow-up was 27 months (range 4-35 months). (3) Results: 38 consecutive patients were considered in this analysis. The overall median PSA level before RT was 1.10 ng/mL (IQR 0.82-2.59). PSA decreased at 3 and 6 months after treatment, with a median value of 0.60 ng/mL (IQR 0.31-0.96; < 0.001) and 0.51 ng/mL (IQR 0.29-1.17; < 0.001), respectively. Overall, biochemical recurrence-free survival (b-RFS) was 15.0 months (95% CI 13-23). Grade-1 toxicity was reported in 31.6% of patients (12/38). (4) Conclusion: These results confirm that Ga-PSMA-11-PET/CT is able to identify the site of recurrence in patients who have failed S-RT, thus supporting the use of metastases-directed radiotherapy as a safe and effective treatment.